Immunotherapy Trials in Head and Neck Cancer

In this video, Barbara Burtness, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses two ongoing trials testing immunotherapy in different settings for patients with head and neck cancer.

The first, a phase III trial, is testing standard of care vs pembrolizumab or chemotherapy plus pembrolizumab in patients with metastatic head and neck cancer.

The second trial is studying the efficacy of pembrolizumab prior to salvage surgery in patients whose disease has recurred after already having received definitive chemoradiation.